All
Researchers Explore Novel Approaches to Boost Immunotherapy Vaccines
March 26th 2015Immunotherapy vaccine approaches that involve harvesting a patient’s dendritic cells and priming them to recognize a tumor-specific antigen before injecting them back into the patient to activate a T-cell response against the tumor have achieved encouraging but limited success.
Lapatinib Flops, Solidifying Standard Treatment of HER2-Positive MBC
March 21st 2015First-line treatment with lapatinib (Tykerb) and a taxane failed to improve progression-free survival (PFS) versus trastuzumab (Herceptin) plus a taxane in patients with HER2-positive metastatic breast cancer, according to final results from the phase III MA.31 trial.
Preclinical Trial Shows Exercise Increases Efficacy of Chemotherapy
March 19th 2015Solid tumors often have an abnormal web of blood vessels, creating areas of hypoxia that protect the tumor from the toxic effects of chemotherapy drugs and radiation, which are designed to seek out well-oxygenated tissue.
Ibrutinib Regimen Delays Disease Progression in Phase III CLL Trial
March 17th 2015Combination therapy with ibrutinib plus bendamustine and rituximab significantly extended progression-free survival compared with BR alone in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma enrolled in the phase III HELIOS trial.
Dinutuximab Approved for High-Risk Neuroblastoma
March 10th 2015Dinutuximab (Unituxin) has been approved by the FDA in combination with interleukin-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), and isotretinoin as a frontline therapy for pediatric patients with high-risk neuroblastoma.
Rindopepimut Gains Breakthrough Designation for EGFRvIII-Positive Glioblastoma
February 23rd 2015The FDA has granted rindopepimut (Rintega) a Breakthrough Therapy Designation for the treatment of adult patients with glioblastoma multiforme (GBM) that test positive for the epidermal growth factor receptor (EGFR) variant (EGFRvIII).
Frontline Revlimid Approved for Multiple Myeloma
February 18th 2015Lenalidomide (Revlimid) plus dexamethasone has been approved by the FDA for the treatment of newly diagnosed patients with multiple myeloma who are not candidates for stem cell transplant, based on findings from the phase III FIRST trial.